Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 18/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13420777 | 0.92 | NOTUM (0.72) | NOTUM | |
| SCHEMBL17026816 | 0.85 | NOTUM (0.54) | NOTUMMEN1ALDH1A1KMT2A | |
| SCHEMBL3452628 | 0.84 | NOTUM (0.45) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4961935 | 0.84 | NOTUM (0.81) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL613112 | 0.84 | NOTUM (0.81) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL23752745 | 0.83 | NOTUM (0.84) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL23752747 | 0.83 | NOTUM (0.84) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5799563 | 0.82 | NOTUM (0.58) | NOTUMKDM4EHSD17B10 | |
| SCHEMBL14507442 | 0.82 | NOTUM (0.59) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL28332852 | 0.80 | NOTUM (0.85) | NOTUMKDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | NOTUM 831/4885KDM4E 3882/4885MEN1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.